{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T18:20:41Z","timestamp":1790274041733,"version":"4.1.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01EB027078"],"award-info":[{"award-number":["R01EB027078"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Biomaterialia"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.actbio.2021.01.020","type":"journal-article","created":{"date-parts":[[2021,1,18]],"date-time":"2021-01-18T23:08:23Z","timestamp":1611011303000},"page":"354-363","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"special_numbering":"C","title":["Human neutrophil membrane-derived nanovesicles as a drug delivery platform for improved therapy of infectious diseases"],"prefix":"10.1016","volume":"123","author":[{"given":"Jin","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6674-5353","authenticated-orcid":false,"given":"Xinyue","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1155-1935","authenticated-orcid":false,"given":"Zhenjia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.actbio.2021.01.020_bib0001","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/nri3399","article-title":"Neutrophil recruitment and function in health and inflammation","volume":"13","author":"Kolaczkowska","year":"2013","journal-title":"Nat. Rev. Immunol."},{"issue":"22","key":"10.1016\/j.actbio.2021.01.020_bib0002","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201706245","article-title":"Neutrophil-based drug delivery systems","volume":"30","author":"Chu","year":"2018","journal-title":"Adv. Mater."},{"issue":"43","key":"10.1016\/j.actbio.2021.01.020_bib0003","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201803618","article-title":"Bioresponsive nanoparticles targeted to infectious microenvironments for sepsis management","volume":"30","author":"Zhang","year":"2018","journal-title":"Adv. Mater."},{"issue":"11","key":"10.1016\/j.actbio.2021.01.020_bib0004","doi-asserted-by":"crossref","first-page":"eaax7964","DOI":"10.1126\/sciadv.aax7964","article-title":"Nanoparticle-induced neutrophil apoptosis increases survival in sepsis and alleviates neurological damage in stroke","volume":"5","author":"Zhang","year":"2019","journal-title":"Sci. Adv."},{"issue":"9530","key":"10.1016\/j.actbio.2021.01.020_bib0005","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0140-6736(06)69005-3","article-title":"Neutrophils in development of multiple organ failure in sepsis","volume":"368","author":"Brown","year":"2006","journal-title":"Lancet"},{"issue":"6116","key":"10.1016\/j.actbio.2021.01.020_bib0006","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1126\/science.1230720","article-title":"Anti-Inflammatory Therapy in Chronic Disease: challenges and Opportunities","volume":"339","author":"Tabas","year":"2013","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.actbio.2021.01.020_bib0007","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/nm.2514","article-title":"The neutrophil in vascular inflammation","volume":"17","author":"Phillipson","year":"2011","journal-title":"Nat. Med."},{"issue":"11","key":"10.1016\/j.actbio.2021.01.020_bib0008","doi-asserted-by":"crossref","first-page":"5271","DOI":"10.1182\/blood-2008-01-078204","article-title":"The vessel wall and its interactions","volume":"111","author":"Wagner","year":"2008","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.actbio.2021.01.020_bib0009","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/nnano.2014.17","article-title":"Prevention of vascular inflammation by nanoparticle targeting of adherent neutrophils","volume":"9","author":"Wang","year":"2014","journal-title":"Nat. Nanotechnol."},{"issue":"2","key":"10.1016\/j.actbio.2021.01.020_bib0010","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1006\/clim.1999.4764","article-title":"Anti-adhesion molecule therapy as an interventional strategy for autoimmune inflammation","volume":"93","author":"Lockwood","year":"1999","journal-title":"Clin. Immunol."},{"issue":"6","key":"10.1016\/j.actbio.2021.01.020_bib0011","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.cell.2010.02.043","article-title":"Anti-inflammatory Agents: present and Future","volume":"140","author":"Dinarello","year":"2010","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.actbio.2021.01.020_bib0012","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1073\/pnas.0907342107","article-title":"Resolvin D1 binds human phagocytes with evidence for proresolving receptors","volume":"107","author":"Krishnamoorthy","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"7395","key":"10.1016\/j.actbio.2021.01.020_bib0013","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nature11042","article-title":"Infection regulates pro-resolving mediators that lower antibiotic requirements","volume":"484","author":"Chiang","year":"2012","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.actbio.2021.01.020_bib0014","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.tips.2015.07.007","article-title":"Resolution pharmacology: opportunities for therapeutic innovation in inflammation","volume":"36","author":"Perretti","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"issue":"8","key":"10.1016\/j.actbio.2021.01.020_bib0015","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1084\/jem.20020760","article-title":"Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals","volume":"196","author":"Serhan","year":"2002","journal-title":"J. Exp. Med."},{"issue":"12","key":"10.1016\/j.actbio.2021.01.020_bib0016","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/j.bbalip.2010.08.002","article-title":"Specialized pro-resolving lipid mediators in the inflammatory response: an update","volume":"1801","author":"Bannenberg","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.actbio.2021.01.020_bib0017","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/1742-2094-8-143","article-title":"Differential aquaporin 4 expression during edema build-up and resolution phases of brain inflammation","volume":"8","author":"Tourdias","year":"2011","journal-title":"J. Neuroinflamm."},{"issue":"3","key":"10.1016\/j.actbio.2021.01.020_bib0018","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.4049\/jimmunol.0900477","article-title":"Effects of low-dose aspirin on acute inflammatory responses in humans","volume":"183","author":"Morris","year":"2009","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.actbio.2021.01.020_bib0019","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1172\/JCI42545","article-title":"Pro-resolving actions and stereoselective biosynthesis of 18S E-series resolvins in human leukocytes and murine inflammation","volume":"121","author":"Oh","year":"2011","journal-title":"J. Clin. Invest."},{"issue":"7268","key":"10.1016\/j.actbio.2021.01.020_bib0020","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1038\/nature08541","article-title":"Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis","volume":"461","author":"Spite","year":"2009","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.actbio.2021.01.020_bib0021","article-title":"Targeting of Nanotherapeutics to Infection Sites for Antimicrobial Therapy","volume":"2","author":"Dong","year":"2019","journal-title":"Adv. Ther.-Germany"},{"key":"10.1016\/j.actbio.2021.01.020_bib0022","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.biomaterials.2017.05.003","article-title":"High yield, scalable and remotely drug-loaded neutrophil-derived extracellular vesicles (EVs) for anti-inflammation therapy","volume":"135","author":"Gao","year":"2017","journal-title":"Biomaterials"},{"issue":"5","key":"10.1016\/j.actbio.2021.01.020_bib0023","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/nnano.2013.54","article-title":"A biomimetic nanosponge that absorbs pore-forming toxins","volume":"8","author":"Hu","year":"2013","journal-title":"Nat. Nanotechnol."},{"issue":"16","key":"10.1016\/j.actbio.2021.01.020_bib0024","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201606209","article-title":"Erythrocyte-platelet hybrid membrane coating for enhanced nanoparticle functionalization","volume":"29","author":"Dehaini","year":"2017","journal-title":"Adv. Mater."},{"issue":"19","key":"10.1016\/j.actbio.2021.01.020_bib0025","doi-asserted-by":"crossref","first-page":"8884","DOI":"10.1039\/c3nr03064d","article-title":"Lipid-insertion enables targeting functionalization of erythrocyte membrane-cloaked nanoparticles","volume":"5","author":"Fang","year":"2013","journal-title":"Nanoscale"},{"key":"10.1016\/j.actbio.2021.01.020_bib0026","article-title":"Generation, purification and engineering of extracellular vesicles and their biomedical applications","author":"Gao","year":"2019","journal-title":"Methods"},{"issue":"2","key":"10.1016\/j.actbio.2021.01.020_bib0027","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1208\/s12248-018-0200-2","article-title":"Targeting inflammatory vasculature by extracellular vesicles","volume":"20","author":"Wang","year":"2018","journal-title":"AAPS J."},{"issue":"2","key":"10.1016\/j.actbio.2021.01.020_bib0028","doi-asserted-by":"crossref","first-page":"e1523","DOI":"10.1002\/wnan.1523","article-title":"Outer membrane vesicles for vaccination and targeted drug delivery","volume":"11","author":"Wang","year":"2019","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"key":"10.1016\/j.actbio.2021.01.020_bib0029","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jconrel.2016.01.024","article-title":"Cell membrane-formed nanovesicles for disease-targeted delivery","volume":"224","author":"Gao","year":"2016","journal-title":"J. Control. Release"},{"issue":"7\u20138","key":"10.1016\/j.actbio.2021.01.020_bib0030","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.clinbiochem.2007.12.021","article-title":"Isolation and activation of human neutrophils in vitro. The importance of the anticoagulant used during blood collection","volume":"41","author":"Freitas","year":"2008","journal-title":"Clin. Biochem."},{"issue":"1","key":"10.1016\/j.actbio.2021.01.020_bib0031","doi-asserted-by":"crossref","first-page":"324","DOI":"10.4049\/jimmunol.1300858","article-title":"beta(2) Integrin-mediated crawling on endothelial ICAM-1 and ICAM-2 is a prerequisite for transcellular neutrophil diapedesis across the inflamed blood-brain barrier","volume":"192","author":"Gorina","year":"2014","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.actbio.2021.01.020_bib0032","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/jlb.64.5.622","article-title":"beta(2)-integrins mediate stable adhesion in collisional interactions between neutrophils and ICAM-1-expressing cells","volume":"64","author":"Lynam","year":"1998","journal-title":"J. Leukocyte Biol."},{"issue":"5","key":"10.1016\/j.actbio.2021.01.020_bib0033","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.immuni.2014.10.008","article-title":"Leukocyte migration into inflamed tissues","volume":"41","author":"Nourshargh","year":"2014","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.actbio.2021.01.020_bib0034","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.smim.2015.05.003","article-title":"New insights into the resolution of inflammation","volume":"27","author":"Gilroy","year":"2015","journal-title":"Semin. Immunol."},{"issue":"3","key":"10.1016\/j.actbio.2021.01.020_bib0035","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.molmed.2019.01.006","article-title":"Is resolution the end of inflammation?","volume":"25","author":"Feehan","year":"2019","journal-title":"Trends Mol. Med."},{"issue":"6","key":"10.1016\/j.actbio.2021.01.020_bib0036","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1021\/acs.molpharmaceut.0c00299","article-title":"Molecular dynamics simulations provide insight into the loading efficiency of proresolving lipid mediators resolvin D1 and D2 in cell membrane-derived nanovesicles","volume":"17","author":"Gc","year":"2020","journal-title":"Mol. Pharm."},{"issue":"1\u20132","key":"10.1016\/j.actbio.2021.01.020_bib0037","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.prostaglandins.2011.01.003","article-title":"Stability and analysis of eicosanoids and docosanoids in tissue culture media","volume":"94","author":"Maddipati","year":"2011","journal-title":"Prostaglandins Other Lipid Mediat."},{"issue":"3","key":"10.1016\/j.actbio.2021.01.020_bib0038","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1089\/sur.2012.084","article-title":"Pseudomonas aeruginosa post-operative peritonitis: clinical features, risk factors, and prognosis","volume":"14","author":"Augustin","year":"2013","journal-title":"Surg. Infect."},{"key":"10.1016\/j.actbio.2021.01.020_bib0039","article-title":"Small is mighty-chemical communication systems in Pseudomonas Aeruginosa","author":"Dela Ahator","year":"2019","journal-title":"Annu. Rev. Microbiol."},{"key":"10.1016\/j.actbio.2021.01.020_bib0040","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.biomaterials.2018.09.042","article-title":"A facile approach for development of a vaccine made of bacterial double-layered membrane vesicles (DMVs)","volume":"187","author":"Wang","year":"2018","journal-title":"Biomaterials"},{"issue":"5","key":"10.1016\/j.actbio.2021.01.020_bib0041","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1055\/a-0748-5548","article-title":"Review of clinical pharmacokinetics of Avibactam, a newly approved non-beta lactam beta-lactamase inhibitor drug, In Combination Use With Ceftazidime","volume":"69","author":"Giri","year":"2019","journal-title":"Drug Res."},{"issue":"10","key":"10.1016\/j.actbio.2021.01.020_bib0042","doi-asserted-by":"crossref","first-page":"5543","DOI":"10.4049\/jimmunol.1003865","article-title":"Cutting edge: humanized nano-proresolving medicines mimic inflammation-resolution and enhance wound healing","volume":"186","author":"Norling","year":"2011","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.actbio.2021.01.020_bib0043","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.coph.2013.05.012","article-title":"Resolution phase lipid mediators of inflammation: agonists of resolution","volume":"13","author":"Serhan","year":"2013","journal-title":"Curr. Opin. Pharmacol."},{"issue":"6","key":"10.1016\/j.actbio.2021.01.020_bib0044","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.ijantimicag.2014.02.009","article-title":"Nanocarriers for antibiotics: a promising solution to treat intracellular bacterial infections","volume":"43","author":"Abed","year":"2014","journal-title":"Int. J. Antimicrob. Agents"}],"container-title":["Acta Biomaterialia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1742706121000477?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1742706121000477?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T17:39:02Z","timestamp":1761673142000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1742706121000477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":44,"alternative-id":["S1742706121000477"],"URL":"https:\/\/doi.org\/10.1016\/j.actbio.2021.01.020","relation":{},"ISSN":["1742-7061"],"issn-type":[{"value":"1742-7061","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Human neutrophil membrane-derived nanovesicles as a drug delivery platform for improved therapy of infectious diseases","name":"articletitle","label":"Article Title"},{"value":"Acta Biomaterialia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.actbio.2021.01.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}